Cyclin dependent kinase degraders and methods of use thereof
AssigneeDifferentiated Therapeutics Inc
InventorsTimothy A. DWIGHT, Bryce K. ALLEN
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for degrading CDK2 and/or CCNE (CCNE1 and/or CCNE2) with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with CDK2 and/or CCNE (CCNE1 and/or CCNE2) with the compounds and compositions of the disclosure.
Claims90
A compound of Formula A-I:
- or a pharmaceutically acceptable salt thereof, wherein:
- s a single or a double bond;
- Ring A is selected from the group consisting of a nitrogen-containing 4-10 member heterocyclyl, a C6-10 aryl and a 5-10-member heteroaryl, wherein the 4-10 member heterocyclyl, C6-10 aryl and 5-10-member heteroaryl are attached to the —NH— through a carbon atom;
- V1 is nitrogen and V2 is carbon, and Ring
- or V2 is nitrogen and V1 is carbon, and Ring
- T is CH or N;
- Q1 and Q2 are independently selected from N and CH;
- R1A is independently selected from H, D, halo, CN, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-4 alkyl, 6-10 membered aryl-C1-4 alkyl-, 4-10 membered heterocyclyl-C1-4 alkyl-, 5-10 membered heteroaryl-C1-4 alkyl-, ORa1, SRa1 NHORa1, C(O)Rb1, C(O)NRa1Ra1, C(O)NRa1(ORa1), C(O)ORa1, OC(O)Rb1, OC(O)NRa1Ra1, NRa1Ra1, NRa1NRa1Ra1, NRa1C(O)Rb1, NRa1C(O)ORa1, NRa1C(O)NRa1Ra1, C(═NRa1)Rb1, C(═NRa1)NRa1Ra1, NRa1C(═NRa1)NRa1Ra1, NRa1C(═NRa1)Rb1, NRa1S(O)NRa1Ra1, NRa1S(O)Rb1, NRa1S(O)2Rb1, NRa1S(O)(═NRa1)Rb1, NRa1S(O)2NRa1Ra1, S(O)Rb1, S(O)NRa1Ra1, S(O)2Rb1, S(O)2NRa1Ra1, OS(O)(═NRa1)Rb1, OS(O)2Rb1, S(O)(═NRa1)Rb1, SF5, P(O)Ra1Rb1, OP(O)(ORa1)(ORa1) and P(O)(ORa1)(ORa1), wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-4 alkyl-, 6-10 membered aryl-C1-4 alkyl-, 4-10 membered heterocyclyl-C1-4 alkyl-, and 5-10 membered heteroaryl-C1-4 alkyl-are each substituted with 0, 1, 2, 3, or 4 independently selected R2 substituents;
- each R2 is independently selected from H, D, halo, CN, NO2, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-7 cycloalkyl, phenyl, 4-7 membered heterocyclyl, 5-6 membered heteroaryl, C3-7 cycloalkyl-C1-4 alkyl-, phenyl-C1-4 alkyl-, 4-7 membered heterocyclyl-C1-4 alkyl-, 5-6 membered heteroaryl-C1-4 alkyl-, ORa2, SRa2, NHORa2, C(O)Rb2, C(O)NRa2Ra2, C(O)NRa2(ORa2), C(O)ORa2, OC(O)Rb2, OC(O)NRa2Ra2, NRa2Ra2, NRa2NRa2Ra2, NRa2C(O)Rb2, NRa2C(O)ORa2, NRa2C(O)NRa2Ra2, C(═NRa2)Rb2, C(═NRa2)NRa2Ra2, NRa2C(═NRa2)NRa2Ra2, NRa2C(═NRa2)Rb2, NRa2S(O)NRa2Ra2, NRa2S(O)Rb2, NRa2S(O)2Rb2, NRa2S(O)(═NRa2)Rb2, NRa2S(O)2NRa2Ra2, S(O)Rb2, S(O)NRa2Ra2, S(O)2Rb2, S(O)2NRa2Ra2, OS(O)(═NRa2)Rb2, OS(O)2Rb2, S(O)(═NRa2)Rb2, SF5, P(O)Ra2Ra2, OP(O)(ORa2)(ORa2) and P(O)(ORa2)(ORa2), wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-7 cycloalkyl, phenyl, 4-7 membered heterocyclyl, 5-6 membered heteroaryl, C3-7 cycloalkyl-C1-4 alkyl-, phenyl-C1-4 alkyl, 4-7 membered heterocyclyl-C1-4 alkyl-, and 5-6 membered heteroaryl-C1-4 alkyl-are each substituted with 0, 1, 2, 3, or 4 substituents independently selected from C1-4 alkyl, C3-7 cycloalkyl, cyclopropyl, oxo, —C(O)C1-4alkyl, —C(O)OC1-4alkyl, —C(O)NH2, —OH, —F, —Cl, —O—C1-4alkyl and —CN;
- each instance of RA is independently selected from —D, halo, CN, C1-4 alkyl, C1-4 haloalkyl, C3-6 cycloalkyl, 4-6 membered heterocyclyl, ORa1, SRa1, SF5, NRa1Ra1, C3-6 cycloalkyl-C1-3 alkyl-, and 4-6 membered heterocyclyl-C1-3 alkyl-, wherein said C1-4 alkyl, C1-4haloalkyl-, C3-6 cycloalkyl, 4-6 membered heterocyclyl-, C3-6 cycloalkyl-C1-3 alkyl-, and 4-6 membered heterocyclyl-C1-3 alkyl are substituted with 0, 1, 2, 3, or 4 substituents independently selected from —D, halo, —OH, —C1-4 alkyl and —OC1-4 alkyl;
- or, alternatively, two RA groups on adjacent atoms of Ring A, together with the ring atoms to which they are attached, form Ring D, wherein Ring D is selected from C3-6 cycloalkyl, 4-6 membered heterocyclyl, phenyl, and 5-6 membered heteroaryl, each of which is substituted with 0, 1, 2, 3, or 4 substituents independently selected from —D, halo, —OH, —C1-4 alkyl and —OC1-4 alkyl;
- each Ra1 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-4 alkyl-, 6-10 membered aryl-C1-4 alkyl-, 4-10 membered heterocyclyl-C1-4 alkyl-, and 5-10 membered heteroaryl-C1-4 alkyl-, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C3-10 cycloalkyl, 6-10 membered aryl, 4-10 membered heterocyclyl, 5-10 membered heteroaryl, C3-10 cycloalkyl-C1-4 alkyl, 6-10 membered aryl-C1-4 alkyl, 4-10 membered heterocyclyl-C1-4 alkyl, and 5-10 membered heteroaryl-C1-4 alkyl are each substituted with 0, 1, 2, 3, or 4 independently selected R2 substituents;
- or two Ra1 groups attached to the same nitrogen atom together with the nitrogen to which they are attached form a 4-7-membered heterocyclyl group substituted with 0, 1, 2, 3, or 4 substituents independently selected from —D, halo, —OH, —C1-4 alkyl and —OC1-4 alkyl;
- each Rb1 is independently selected from C1-6 alkyl, C1-6 hydroxyalkyl, C3-9 cycloalkyl and C2-6 heteroalkyl;
- each Ra2 is independently selected from H, C1-6 alkyl, C1-6 hydroxyalkyl, C3-9 cycloalkyl and C2-6 heteroalkyl, or, when possible, two instances of Ra2 and the atom to which they are attached are taken together to form a 4-7 member heterocycle substituted with 0, 1, 2, 3, or 4 substituents independently selected from —D, halo, —OH, —C1-4 alkyl and —OC1-4 alkyl;
- each Rb2 is independently selected from C1-6 alkyl, C1-6 hydroxyalkyl, C3-9 cycloalkyl and C2-6 heteroalkyl;
- X is X1 when Ring A is heterocyclyl and is selected from X1 and X2 when Ring A is aryl or heteroaryl;
- X1 is selected from —S(O)2— and —C(O)—;
- X2 is selected from —O—, —NH—, —N(CH3)— and —CH2—;
- L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched C1-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by —Cy—, —CH(R)—, —C(R)2—, —O—, —NR—, —S—, —OC(═O)—, —C(═O)O—, —C(═O)—, —S(═O)—, —S(═O)2—, —NRS(═O)2—, —S(═O)2NR—, —NRC(═O)—, —C(═O)NR—, —OC(═O)NR— or —NRC(═O)O—, wherein:
- each —Cy— is independently a bivalent ring selected from phenylene, an 8-10 membered bicyclic arylene, a 4-7 membered monocyclic carbocyclylene, a 5-11 membered Spiro carbocyclylene, a 4-10 membered bicyclic carbocyclylene, a 5-10 membered bridged carbocyclylene, a 4-7 membered monocyclic heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-11 membered spiro heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 4-10 membered bicyclic heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bridged bicyclic saturated or partially unsaturated heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroarylene having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein each phenylene, arylene, carbocyclylene, heterocyclylene and heteroarylene is substituted with 0, 1, 2, 3, or 4 instances of RC;
- LBM is selected from:
- Ya is CH or N;
- Za is a bond, —CH2—, —NH—, O, or —NHC(O)— where NH of —NHC(O)— is attached to Ya;
- Ring B is phenylene, a 4-10-membered heterocyclylene, a 5-6-membered monocyclic heteroarylene or a 9-10-membered fused bicyclic heteroarylene, wherein each heteroarylene contains one to three nitrogen ring atoms.
- ring C together with the (R4)r substituents is selected from the group consisting of:
- each instance of Re is independently selected from —D, halogen, —OH, and —C1-6 alkyl;
- each instance of R4 is independently selected from —D, halogen, —OH, and —C1-6 alkyl;
- each instance of R5 is independently selected from —D, halogen, —OH, and —C1-6 alkyl;
- each instance of R is independently selected from hydrogen and —C1-6 alkyl;
- n is 0, 1, 2, 3, or 4;
- r is 0, 1, 2, 3, or 4;
- and
- s is 0, 1, 2, 3, or 4.
A compound of Formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- Ring A is selected from
- each W1, W2, W3 and W4 is independently selected from CH and N, provided that no more than 2 of W1, W2, W3 and W4 are N;
- T is CH or N;
- R1 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocyclyl, C3-10 cycloalkyl-C1-4 alkyl- and 4-10 membered heterocyclyl-C1-4 alkyl-, wherein said C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, 4-10 membered heterocyclyl, C3-10 cycloalkyl-C1-4 alkyl- and 4-10 membered heterocyclyl-C1-4 alkyl-, are each substituted with 0, 1, 2, 3, or 4 independently selected R2 substituents;
- each R2 is independently selected from D, halo, CN, C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, ORa2, C(O)Rb2, C(O)NRa2Ra2, C(O)ORa2, OC(O)Rb2, OC(O)NRa2Ra2, NRa2Ra2, NRa2C(O)Rb2, NRa2C(O)ORa2, NRa2C(O)NRa2Ra2, NRa2S(O)NRa2Ra2, NRa2S(O)Rb2, NRa2S(O)2Rb2, NRa2S(O)2NRa2Ra2, S(O)Rb2, S(O)NRa2Ra2, S(O)2Rb2, S(O)2NRa2Ra2, SF5, wherein said C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl and 4-7 membered heterocyclyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-4 alkyl, C3-7 cycloalkyl, cyclopropyl, oxo, —C(O)C1-4alkyl, —C(O)OC1-4alkyl, —C(O)NH2, —OH, —F, —Cl, —O—C1-4alkyl and —CN;
- each Ra2 is independently selected from H, C1-6 alkyl, C1-6 hydroxyalkyl, C3-9 cycloalkyl and C2-6 heteroalkyl, or, when possible, two instances of Ra2 and the atom to which they are attached are taken together to form a saturated 3-7-membered heterocycle;
- each Rb2 is independently selected from C1-6 alkyl, C1-6 hydroxyalkyl, C3-9 cycloalkyl and C2-6 heteroalkyl;
- L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched C1-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by —Cy—, —CH(R)—, —C(R)2—, —O—, —NR—, —S—, —OC(═O)—, —C(═O)O—, —C(═O)—, —S(═O)—, —S(═O)2—, —NRS(═O)2—, —S(═O)2NR—, —NRC(═O)—, —C(═O)NR—, —OC(═O)NR— or —NRC(═O)O—, wherein:
- each —Cy— is independently a bivalent ring selected from phenylene, an 8-10 membered bicyclic arylene, a 4-7 membered monocyclic carbocyclylene, a 5-11 membered spiro carbocyclylene, a 4-10 membered bicyclic carbocyclylene, a 5-10 membered bridged carbocyclylene, a 4-7 membered monocyclic heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-11 membered spiro heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 4-10 membered bicyclic heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-10 membered bridged bicyclic saturated or partially unsaturated heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroarylene having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein each phenylene, arylene, carbocyclylene, heterocyclylene and heteroarylene is substituted with 0, 1, 2, 3, or 4 instances of RC;
- LBM is selected from
- each instance of RA is independently selected from —D, halogen, —C1-6 alkyl, —OH and —OC1-4 alkyl, wherein each —C1-6 alkyl is substituted with 0, 1, 2 or 3 groups independently selected from —D, —F, —OH and —OC1-4 alkyl or two RA groups on adjacent atoms of Ring A, together with the ring atoms to which they are attached, form Ring D, wherein Ring D is selected from C3-6 cycloalkyl, 4-6 membered heterocyclyl, phenyl, and 5-6 membered heteroaryl, each of which is substituted with 0, 1, 2, 3, or 4 substituents independently selected from —D, halo, —OH, —C1-4 alkyl and —OC1-4 alkyl;
- each instance of RC is independently selected from —D, halogen, —OH, and —C1-6 alkyl;
- each instance of R4 is independently selected from —D, halogen, —OH, and —C1-6 alkyl;
- each instance of R5 is independently selected from —D, halogen, —OH, and —C1-6 alkyl;
- each instance of R is independently selected from hydrogen and —C1-6 alkyl;
- n is 0, 1, 2, 3, or 4;
- r is 0, 1, 2, 3, or 4;
- and
- s is 0, 1, 2, 3, or 4.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.